Eli Lilly released the full topline data from the TRIUMPH-4 trial this week, and the picture is more complicated than the headline numbers suggest. The headline numbers themselves are striking. Patients on retatrutide 12 mg lost an average of 71.2 pounds—roughly 28.7% of starting body weight—at 68 weeks. Knee pain measured by the WOMAC scale dropped by up to 75.8%, with more than one in eight patients on retatrutide reporting complete freedom from knee pain at end of trial. (Eli Lilly investor release; BioSpace)

Those numbers, in the right framing, will make retatrutide the most efficacious obesity drug ever submitted to the FDA. The framing matters, though, because TRIUMPH-4 also produced two safety signals that deserve a closer read than they’re getting in the launch coverage.

The Triple Agonist Mechanism

Retatrutide is a first-in-class triple agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. That’s one more receptor than tirzepatide, which activates GLP-1 and GIP, and two more than semaglutide, which activates GLP-1 only.

The glucagon receptor activation is what makes this molecule mechanistically distinct. Glucagon drives hepatic glucose output and promotes lipolysis—the breakdown of stored fat. In theory, adding glucagon agonism to GLP-1’s appetite suppression and GIP’s insulin sensitization creates a triple metabolic hit: eat less, burn more fat, improve metabolic health on multiple axes simultaneously. That theory is now supported by Phase 3 data, which is a different kind of evidence than the Phase 2 picture that prompted Lilly to invest in one of the largest Phase 3 obesity programs in pharmaceutical history. Seven additional TRIUMPH program readouts are expected in 2026.

What Joint Pain Relief Adds to the Picture

TRIUMPH-4 wasn’t designed only to test weight loss. It was designed to test whether retatrutide-driven weight loss translates into measurable functional improvement in patients with knee osteoarthritis—a population in which obesity-driven joint loading is a major contributor to disease progression.

The trial enrolled adults with obesity or overweight and knee osteoarthritis. The co-primary endpoints were weight change and WOMAC pain score change at 68 weeks. Retatrutide hit both. WOMAC pain reductions of up to 75.8% are an order-of-magnitude improvement over what intra-articular hyaluronic acid injections, NSAIDs, or duloxetine produce in similar populations.

That’s a meaningful finding in its own right. Obesity drugs have largely been evaluated as obesity drugs—the unstated assumption is that the weight loss itself is the therapeutic outcome. TRIUMPH-4 reframes the question: what diseases driven by obesity actually improve when the obesity is treated aggressively? Knee osteoarthritis is the first answer. Sleep apnea, metabolic dysfunction-associated steatotic liver disease, cardiovascular outcomes, and chronic low back pain are all on the TRIUMPH-program calendar.

The Discontinuation Numbers

This is where the picture gets more interesting.

Discontinuation due to adverse events ran 12.2% on retatrutide 9 mg, 18.2% on retatrutide 12 mg, and 4.0% on placebo. Nearly one in five patients on the highest dose stopped treatment because of side effects. (FierceBiotech)

Lilly notes that these discontinuation rates “were highly correlated with baseline BMI and included discontinuations for perceived excessive weight loss.” That phrase—”perceived excessive weight loss”—is doing a lot of work. It means some patients lost weight so rapidly that either they or their physicians decided to stop treatment, not because of a traditional adverse event but because the drug was working too aggressively.

Whether you file “too much weight loss” as a safety problem or an efficacy feature depends on your perspective. From a clinical standpoint, excessive or too-rapid weight loss carries real risks: gallstone formation, muscle mass loss, micronutrient deficiencies, and metabolic adaptation that can make weight regain more aggressive when the drug is stopped. From a regulatory standpoint, an 18% discontinuation rate at the top dose is high enough that the FDA will scrutinize it closely. The label, if approved, will likely emphasize titration and prescriber-managed dose escalation more aggressively than the tirzepatide label does.

The Dysesthesia Signal

This is the finding that deserves more public attention than it’s getting.

Dysesthesia—abnormal skin sensations including burning, tingling, prickling, or numbness—was reported in 0.7% of placebo patients, 8.8% of retatrutide 9 mg patients, and 20.9% of retatrutide 12 mg patients. That’s a roughly 30-fold increase over placebo at the highest dose, and a 12-fold increase at the dose Lilly is most likely to advance into clinical practice.

Dysesthesia is not in the established adverse event profile of GLP-1 or dual GLP-1/GIP agonists. It is plausibly related to glucagon receptor activation—glucagon has known effects on hepatic and metabolic function that can affect peripheral nerve glucose handling, and rapid weight loss itself can drive transient peripheral neuropathies. The mechanism is unresolved, and the duration and reversibility of the symptom in TRIUMPH-4 patients haven’t been fully characterized in public materials yet.

What is clear: this is a new safety signal that wasn’t visible in retatrutide’s Phase 2 data, and a 20% rate at the high dose is not a rounding error. Whether it improves with longer treatment, resolves on dose reduction, or persists as a meaningful tolerability constraint will be one of the most important things to track across the seven additional TRIUMPH readouts in 2026.

Where Retatrutide Sits Now

TRIUMPH-4 results land in a GLP-1 and obesity drug landscape that is already crowded and moving fast. Tirzepatide holds the current market leader position in the dual-agonist category, with approved indications for both diabetes and obesity. Retatrutide is Lilly competing against itself—a triple agonist designed to supersede its own dual agonist.

Viking Therapeutics’ VK2735, a GLP-1/GIP dual agonist, has fully enrolled both VANQUISH-1 and VANQUISH-2 Phase 3 trials, with topline results expected in 2027 and 2028. Amgen’s MariTide—a GLP-1 receptor agonist plus GIP receptor antagonist with monthly dosing—has begun its Phase 3 MARITIME program after producing up to 20% weight loss in Phase 2. Boehringer’s survodutide, a GLP-1/glucagon dual agonist, just reported 16.6% weight loss in its first Phase 3 trial. Pfizer’s PF-3944 amylin agonist data is on the calendar for the ADA Scientific Sessions in June. The pipeline is no longer a one-mechanism story.

For the head-to-head comparison of retatrutide and tirzepatide, including evidence tier, mechanism details, and current trial readouts, our comparison guide walks through the full picture. The full retatrutide compound article (forthcoming) will cover the complete trial program as additional 2026 data arrives.

What to Watch From Here

Three things will determine whether retatrutide’s headline efficacy translates into the dominant obesity drug of the late 2020s.

The remaining seven TRIUMPH readouts will tell us whether the efficacy holds across populations—Type 2 diabetes, sleep apnea, MASLD, cardiovascular outcomes—and whether the dysesthesia signal is consistent across indications or specific to the osteoarthritis population studied in TRIUMPH-4. The diabetes data, in particular, will inform whether glucagon receptor activation creates problems with glycemic control that aren’t visible in non-diabetic obese patients.

The FDA’s tolerability assessment will weigh the discontinuation and dysesthesia data against the unprecedented efficacy. An 18% discontinuation rate at the top dose is not disqualifying, but the label will likely require titration discipline and may restrict the 12 mg dose to physician-managed escalation rather than open use.

Head-to-head data against tirzepatide is the question that will ultimately decide market position. Retatrutide produces meaningfully more weight loss than tirzepatide produces—that’s not in dispute—but whether the incremental benefit justifies the incremental adverse event burden is exactly the kind of question patients, physicians, and payers will ask. The data to answer it doesn’t exist yet. Lilly will be expected to produce it.

References

1. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Eli Lilly Investor Release. Eli Lilly
2. Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges. BioSpace. 2026. BioSpace
3. Eli Lilly’s obesity triple-threat smashes efficacy expectations Phase 3 proves intolerable. FierceBiotech. 2026. FierceBiotech
4. Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial. Clinical Trials Arena. 2026. Clinical Trials Arena
5. Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial. PharmExec. 2026. PharmExec